Lyell, Cellares to evaluate automated manufacturing of its CAR T-Cell Therapy

Cellares and Lyell Immunopharma announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle, through Cellares’ Technology Adoption Partnership program. As part of the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the manufacture of Lyell’s LYL797 CAR T-cell therapy, using the Cell Shuttle. “We are excited to work with Cellares to evaluate their innovative automated manufacturing processes as part of our overall manufacturing strategy to efficiently, rapidly, and cost-effectively scale manufacturing capacity for our CAR T-cell product candidates for future clinical trials and potential commercialization,” said Stephen Hill, Chief Operating Officer of Lyell. “We are impressed with the progress Cellares has made with their manufacturing capabilities, and the commitment and vision of the Cellares team to apply these technologies to help deliver new and potentially transformative therapies to patients.”